Evidence map›Paper›PMID 40282990›Full record

ArticleMedicina (Kaunas, Lithuania)2025

ATRX, OLIG2, MGMT, and IDH2 in Glioblastoma: Essential Molecular Mechanisms and Therapeutic Significance.

Andrea Pop-Crisan, Radu Pirlog, Lavinia-Lorena Pruteanu, Constantin Busuioc, Ovidiu-Laurean Pop, Deo Prakash Pandey, Cornelia Braicu, Ioana Berindan-Neagoe

Abstract read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrea Pop-CrisanDepartment of Surgical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
Radu PirlogDepartment of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hațieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
Lavinia-Lorena PruteanuDepartment of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hațieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
Constantin BusuiocDepartment of Pathology, Spitalul Clinic Sfanta Maria, Bulevardul Ion Mihalache 37-39, 011172 București, Romania.
Ovidiu-Laurean PopDepartment of Surgical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
Deo Prakash PandeyCentre for Embryology and Healthy Development, Department of Microbiology, Rikshospitalet, Oslo University Hospital, 0372 Oslo, Norway.ORCID 0000-0001-5493-3197
Cornelia BraicuDepartment of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hațieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.ORCID 0000-0002-3055-4747
Ioana Berindan-NeagoeDoctoral School Iuliu Haţieganu, University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.ORCID 0000-0001-5828-1325

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain NeoplasmsDNA Modification MethylasesDNA Repair EnzymesGlioblastomaIsocitrate DehydrogenaseOligodendrocyte Transcription Factor 2Tumor Suppressor ProteinsX-linked Nuclear ProteinBiomarkers, TumorHumansATRX protein, humanBiomarkers, TumorDNA Modification MethylasesDNA Repair EnzymesIDH2 protein, humanIsocitrate DehydrogenaseMGMT protein, humanOLIG2 protein, humanOligodendrocyte Transcription Factor 2Tumor Suppressor ProteinsX-linked Nuclear Proteinglioblastomamolecular alterationtherapeutic strategy

Identifiers

PMID40282990
PMCPMC12028847

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.